



Press release from Emotra AB (publ)

Göteborg, October 7, 2021

EMOTRA AB: A candidate for the board of directors has notified us that he is presently not available for appointment

Emotra has been informed by a candidate for new director, Jan Samzelius, that he at present is not available for appointment to Emotra's board of directors at tomorrow's extraordinary shareholder meeting.

On August 31, 2021, Emotra announced that the company had reached an agreement with the shareholders of NeuraMetrix, Inc. to acquire all outstanding shares in NeuraMetrix, Inc. The acquisition requires approval at an extraordinary shareholder meeting, as well as the meeting passing a resolution that grants the board of directors the authority to issue Replacement shares. The extraordinary shareholder meeting in Emotra AB is scheduled for tomorrow, October 8, 2021.

In the notice for the extraordinary shareholder meeting, which was published on September 6, 2021, we announced our proposal to change the company name to NeuraMetrix AB. The notice also contained information about the proposal for a new board of directors.

Jan Samzelius has now informed us that he for personal reasons is presently not available for appointment to the board of directors.

He will, however, continue to be involved in the continued development of NeuraMetrix's operations.

For further information about Emotra, please contact:

Daniel Poté, CEO, telephone: +46 73 234 41 93, E-mail: daniel@emotra.se daniel@emotra.se

Emotra AB (publ) is a medical technology company that carries out research, development, clinical studies and marketing in the area of mental health. The Company's method, EDOR®, is a proprietary and objective psychophysiological test for identifying hyporeactive patients.